Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255566 | 1.00 | USP2 (0.49) | USP2MAOBTRIM24HPGDNR1H4 | |
| SCHEMBL2967940 | 0.86 | TRIM24 (0.55) | TRIM24HPGDNR1H4KAT6A | |
| SCHEMBL12243375 | 0.85 | SCN4A (0.49) | USP2MAOB | |
| SCHEMBL3575374 | 0.85 | SCN4A (0.49) | USP2MAOB | |
| SCHEMBL29120475 | 0.85 | USP2 (0.47) | USP2MAOBMRGPRX4 | |
| SCHEMBL8681888 | 0.85 | SCN4A (0.49) | USP2MAOB | |
| SCHEMBL5663833 | 0.82 | USP2 (0.45) | USP2MAOBMRGPRX4 | |
| SCHEMBL5662940 | 0.82 | USP2 (0.45) | USP2MAOBMRGPRX4 | |
| SCHEMBL14227138 | 0.82 | MAOB (0.46) | USP2MAOBMRGPRX4 | |
| SCHEMBL13251358 | 0.81 | TDP1 (0.49) | MAOBHPGDNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279687-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | USP2 4856/4885MAOB 76/4885TRIM24 3055/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | USP2 4724/4885MAOB 105/4885TRIM24 2938/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | USP2 4719/4885MAOB 99/4885TRIM24 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.